LifeMap Sciences' VarElect phenotyper may have positive global results

LifeMap Sciences, Inc. recently announced the commercial release of VarElect, a powerful, user-friendly application for organizing gene variants resulting from next generation sequencing experiments.

VarElect prioritizes gene variants according to their potential association to a disease or phenotype of interest. It can also help in identifying the roles of genes and their variants in biological processes, health and disease, and at a rapid rate.

VarElect is an integral part of LifeMap Sciences’ NGS platform, which also includes GeneAnalytics, a gene analysis tool. Both VarElect and GeneAnalytics are part of the GeneCards Plus suite, which was only launched in 2014.

“We are delighted to see how our robust integrated data platform and GeneCards advanced search capabilities gave birth to a new and highly effective gene variant prioritization tool that we and our companion groups use every day in our NGS decipherment endeavors,” said Doron Lancet, Ph.D., professor at the Crown Human Genome Center at the Weizmann Institute of Science.

LifeMap is the exclusive worldwide license holder to market GeneCards, MalaCards, GeneAlaCart and VarElect from Yeda Research and Development Company Ltd., which is the commercial arm of the Weizmann Institute.

LifeMap Sciences CEO David Warshawsky, Ph.D. added that the VarElect releases will have positive implications on a global level.

“We believe that VarElect will enable scientists worldwide to cost effectively utilize unprecedented amounts of genetic data from whole exome and genome experiments,” Warshawsky said.